ATE439829T1 - Gel oder lísung enthaltend dihydrotestosterone, deren herstellungsverfahren und verwendung - Google Patents
Gel oder lísung enthaltend dihydrotestosterone, deren herstellungsverfahren und verwendungInfo
- Publication number
- ATE439829T1 ATE439829T1 AT01403166T AT01403166T ATE439829T1 AT E439829 T1 ATE439829 T1 AT E439829T1 AT 01403166 T AT01403166 T AT 01403166T AT 01403166 T AT01403166 T AT 01403166T AT E439829 T1 ATE439829 T1 AT E439829T1
- Authority
- AT
- Austria
- Prior art keywords
- dht
- gel
- production
- solution containing
- dihydrotestosterone
- Prior art date
Links
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 title abstract 5
- 229960003473 androstanolone Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 229940124532 absorption promoter Drugs 0.000 abstract 2
- 239000003349 gelling agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Prostheses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01403166A EP1317921B1 (de) | 2001-12-07 | 2001-12-07 | Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE439829T1 true ATE439829T1 (de) | 2009-09-15 |
Family
ID=8183007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01403166T ATE439829T1 (de) | 2001-12-07 | 2001-12-07 | Gel oder lísung enthaltend dihydrotestosterone, deren herstellungsverfahren und verwendung |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20030087885A1 (de) |
| EP (1) | EP1317921B1 (de) |
| AT (1) | ATE439829T1 (de) |
| AU (1) | AU2002364625A1 (de) |
| CA (1) | CA2469028C (de) |
| CY (1) | CY1110602T1 (de) |
| DE (1) | DE60139625D1 (de) |
| DK (1) | DK1317921T3 (de) |
| ES (1) | ES2330188T3 (de) |
| MX (1) | MXPA04005517A (de) |
| PT (1) | PT1317921E (de) |
| WO (1) | WO2003047548A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| DE20121209U1 (de) * | 2000-12-22 | 2002-06-20 | August Wolff Gmbh & Co Arzneim | Gelzusammensetzung zur Behandlung von Hypogonadismus |
| US20040072810A1 (en) * | 2001-11-07 | 2004-04-15 | Besins International Belgique | Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof |
| EP1952809B1 (de) * | 2002-12-18 | 2017-08-02 | Besins Healthcare Luxembourg SARL | Formulierungen für die Reduzierung der Brustdichte mit 4-Hydroxi-Tamoxifen |
| EP1572178B1 (de) * | 2002-12-18 | 2006-05-03 | Laboratoires Besins International | Behandlung von mastalgie mit4-hydroxy-tamoxifen |
| ES2483896T3 (es) * | 2003-04-01 | 2014-08-08 | Besins Healthcare Luxembourg Sarl | Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen |
| NZ544031A (en) * | 2003-06-09 | 2008-08-29 | Univ Northwestern | Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen |
| US20050036953A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of ammonium lactate |
| US20050037040A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of urea and ammonium lactate |
| US20050042182A1 (en) * | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
| MXPA06000474A (es) * | 2003-07-11 | 2007-06-05 | Macrochem Corp | Composiciones farmaceuticas para aplicaciones topicas. |
| US20050025833A1 (en) * | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| EP1550440A1 (de) * | 2003-12-15 | 2005-07-06 | Laboratoires Besins International | Verwendung von 4-hydroxytamoxifen zur Herstellung eines Arzneimittels zur Behandlung von Gynäkomastie |
| JP5069469B2 (ja) * | 2003-12-15 | 2012-11-07 | ラボラトワール ブザン アンテルナスィヨナル | 女性化乳房治療用の薬剤を製造する際の４−ヒドロキシタモキシフェンの使用 |
| US7968532B2 (en) * | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| US20050208139A1 (en) * | 2004-03-22 | 2005-09-22 | Ascend Therapeutics, Inc. | Chemically stable compositions of 4-hydroxy tamoxifen |
| US7507769B2 (en) * | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| EP1748770B1 (de) * | 2004-03-22 | 2008-04-09 | Laboratoires Besins International | 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen |
| EP1579856A1 (de) * | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | 4-Hydroxytamoxifen zur Behandlung von benignen Brusterkrankungen |
| EP1634583A1 (de) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterongele enthaltend Propylenglykol als Resorptionsverstärker |
| EA013430B1 (ru) * | 2004-09-09 | 2010-04-30 | Лаборатуар Безен Энтернасьональ | Тестостероновые гели, включающие пропиленгликоль в качестве усилителя проницаемости |
| KR20080016552A (ko) * | 2005-04-13 | 2008-02-21 | 유니메드 파마슈티칼스, 인크. | 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법 |
| SI1937276T1 (sl) | 2005-10-12 | 2013-04-30 | Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road | Izboljšani testosteronski gel in postopek uporabe |
| AU2012200290B2 (en) * | 2005-10-19 | 2014-08-21 | Havah Therapeutics Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| JP5449775B2 (ja) | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
| EP2731634A4 (de) * | 2011-07-14 | 2014-12-31 | Sunnywipes Pty Ltd | Desinfizierende formulierungen und verwendungen davon |
| EP3209301B1 (de) | 2014-10-22 | 2023-06-07 | Havah Therapeutics Pty Ltd | Verfahren zur reduzierung der mammografischen brustdichte und/oder des brustkrebsrisikos |
| EP3364978A4 (de) | 2015-10-22 | 2019-06-05 | Havah Therapeutics Pty Ltd | Verfahren zur reduzierung der mammografischen brustdichte und/oder des brustkrebsrisikos |
| CN109276539A (zh) * | 2018-11-08 | 2019-01-29 | 北京海霞润月更年期综合症医学研究院 | 一种睾酮凝胶及制备方法 |
| CA3142193A1 (en) | 2019-06-03 | 2020-12-10 | Havah Therapeutics Pty Ltd | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2519252A1 (fr) | 1982-01-07 | 1983-07-08 | Besins Jean | Medicament a base de dihydrotestosterone pour le traitement des deficits des secretions androgeniques testiculaires |
| US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
| EP0952833A1 (de) * | 1996-05-02 | 1999-11-03 | Azupharma GmbH | Topische penile androgen-applikation zur behandlung der erektilen dysfunktion |
| US6562369B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers |
-
2001
- 2001-12-07 DK DK01403166T patent/DK1317921T3/da active
- 2001-12-07 DE DE60139625T patent/DE60139625D1/de not_active Expired - Lifetime
- 2001-12-07 AT AT01403166T patent/ATE439829T1/de active
- 2001-12-07 EP EP01403166A patent/EP1317921B1/de not_active Expired - Lifetime
- 2001-12-07 ES ES01403166T patent/ES2330188T3/es not_active Expired - Lifetime
- 2001-12-07 PT PT01403166T patent/PT1317921E/pt unknown
-
2002
- 2002-03-13 US US10/099,725 patent/US20030087885A1/en not_active Abandoned
- 2002-12-04 WO PCT/FR2002/004176 patent/WO2003047548A1/fr not_active Ceased
- 2002-12-04 AU AU2002364625A patent/AU2002364625A1/en not_active Abandoned
- 2002-12-04 CA CA2469028A patent/CA2469028C/fr not_active Expired - Lifetime
- 2002-12-04 MX MXPA04005517A patent/MXPA04005517A/es active IP Right Grant
-
2009
- 2009-10-30 CY CY20091101134T patent/CY1110602T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04005517A (es) | 2005-03-23 |
| US20030087885A1 (en) | 2003-05-08 |
| WO2003047548A1 (fr) | 2003-06-12 |
| EP1317921A1 (de) | 2003-06-11 |
| DK1317921T3 (da) | 2009-12-21 |
| CY1110602T1 (el) | 2015-04-29 |
| AU2002364625A1 (en) | 2003-06-17 |
| CA2469028A1 (fr) | 2003-06-12 |
| PT1317921E (pt) | 2009-11-06 |
| DE60139625D1 (de) | 2009-10-01 |
| EP1317921B1 (de) | 2009-08-19 |
| ES2330188T3 (es) | 2009-12-07 |
| CA2469028C (fr) | 2012-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60139625D1 (de) | Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung | |
| DE69739856D1 (de) | Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen | |
| HU9201329D0 (en) | The use of sulphonamides for medical purpose and process for the production of new sulphonamides | |
| DK0433225T3 (da) | Fremgangsmåde til fremstilling af biologisk aktivt protein, f.eks. TGF | |
| ATE312103T1 (de) | Substituierte porphyrine und deren therapeutische verwendungen | |
| BR0007781A (pt) | Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf | |
| BR0209777A (pt) | Formulações lìquidas estáveis | |
| BRPI0415398A (pt) | composto, composição farmacêutica, processo para a preparação da mesma, uso de um composto, método de tratamento de cáncer, e, processo para preparação de um composto | |
| SE8102193L (sv) | Terapeutiskt aktiv organisk forening och dess anvendning | |
| ATE235459T1 (de) | Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren | |
| DK15589D0 (da) | Kemiske forbindelser | |
| ATE509004T1 (de) | 3-alkylierte 5,5',6,6',7,7',8,8'-octahydro-2, 2'binaphthole und 3,3'-dialkylierte 5,5',6,6',7, 7',8,8'-octahydro-2,2'-binaphthole sowie herstellungsverfahren dafür | |
| ATE293595T1 (de) | Thyroidhormon-analoga und verfahren zu ihrer herstellung | |
| ATE306934T1 (de) | Von willenbrand faktor (vwf) enthaltende zubereitung, verfahren zür herstellung von vwf enthaltenden zubereitungen und deren verwendung | |
| WO2003087049A3 (de) | Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum | |
| DE59608422D1 (de) | Verfahren zur Herstellung von Poly(diorganosiloxanen), Mischungen, enthaltend diese Poly(diorganosiloxane) und deren Verwendung | |
| DE69533043D1 (de) | Acrylamid-derivate und verfahren zu deren herstellung | |
| HUT54988A (en) | Process for producing substituted n-(quinolin-2-ylmethoxy)-benzylsulfonylureas and pharmaceutical compositions comprising such compounds | |
| HUT57205A (en) | Process for producing cycloalkano/b/-indol derivatives and pharmaceutical compositions containing them | |
| ES2059457T3 (es) | Utilizacion de bezafibrato para el tratamiento de la diabetes. | |
| ATE85623T1 (de) | Fibrin(ogen) derivate, verfahren zu ihrer herstellung und ihre vewendung. | |
| BRPI0415497A (pt) | composto processo para a sua preparação , composição farmacêutica que compreende o mesmo, utilização de um composto e método para o tratamento de diabetes do tipo ii | |
| PT83929B (pt) | Processo de preparacao de 3-benzazepinas substituidas por sulfinilo e sulfonilo e das composicoes farmaceuticas que as contem | |
| ATE153032T1 (de) | Zyklische angiopeptin derivate, deren herstellung und pharmazeutische zusammensetzungen | |
| ATE80625T1 (de) | 2-benzimidazolylalkylthio(oder sulfinyl- oder sulfonyl)-derivate, verfahren zu deren herstellung und deren anwendung als arzneimittel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEFA | Change of the company name | ||
| UEP | Publication of translation of european patent specification |
Ref document number: 1317921 Country of ref document: EP |